NCT02609958View on ClinicalTrials.gov

ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 16, 2015

Primary Completion Date

July 7, 2017

Study Completion Date

October 11, 2017

Conditions

Cholangiocarcinoma

Interventions

DRUG

Varlitinib

"varlitinib tablets with:~1. starting dose: 300mg BID~2. target dose: 400mg BID~3. dose modification by investigator allowed between 200mg BID to 500mg BID"

Trial Locations (3)

Unknown

Singapore

Seoul

Taipei